Movement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment

Market Focus

Jul 31

On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.

According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.

Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1174279530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174279530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174279530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174279530","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment","media":"Market Focus","content":"<p><p>On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.</p><p>According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.</p><p>Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 5.47% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% Year-over-Year Boosting Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 13:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.</p><p>According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.</p><p>Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1174279530","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174279530","pubTimestamp":1785474233,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨5.47%，CARVYKTI第二季度销售额同比飙升近50%，提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On July 31, GENSCRIPT BIO rose 5.47% in regular trading, trading at HK$18.29/share, with turnover of HK$292 million. The stock's gain was driven by strong quarterly sales data from its associate company Legend Biotech's flagship CAR-T therapy CARVYKTI.According to a company filing, Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% increase year-over-year and extending its robust growth trajectory. The sales figure was provided by collaboration partner Janssen Biotech under their cooperation and license agreement originally signed in December 2017. Neither Legend Biotech nor GENSCRIPT BIO independently verified the accuracy of the figure.Beyond the commercial momentum of CARVYKTI, GENSCRIPT BIO's pipeline also showed progress, with Legend Biotech's potentially first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy LB2501 achieving clinical proof-of-concept in relapsed/refractory B-cell non-Hodgkin lymphoma patients in June, demonstrating dose-dependent CAR-T cell expansion without lymphodepletion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}